

**Amendments to the Claims**

Please cancel Claims 2, 4-14, 16 and 18-29.

Please amend Claims 1, 3, 15 and 17.

Please add new Claims 30-45.

The Claim Listing below will replace all prior versions of the claims in the application:

**Claim Listing**

1. (Currently Amended) ~~A chimeric~~ An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising at least part of a human immunoglobulin constant region and at least part of a non-human immunoglobulin variable region, wherein said antibody or antigen-binding fragment capable of binding an epitope specific for (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human tumor necrosis factor TNF  $\alpha$ , and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>).
2. (Canceled).
3. (Currently Amended) ~~A chimeric~~ The antibody or antigen-binding fragment according to claim 1, wherein said chimeric antibody or antigen-binding fragment comprises two light chains and two heavy chains, each of said chains comprising at least part of a human constant region and at least part of a human variable region, said variable region capable of binding an epitope of human TNF $\alpha$ .

Claims 4-14. (Canceled).

15. (Currently Amended) ~~A chimeric~~ An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising at least part of a human IgG1 constant region, wherein said antibody or antigen-binding fragment and at least part of a non-human immunoglobulin variable region, said antibody capable of binding an epitope

~~specific for~~ (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF $\alpha$ , and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant (K<sub>a</sub>).

16. (Canceled).

17. (Currently Amended) ~~A chimeric~~ The antibody or antigen-binding fragment thereof according to claim 15, wherein said ~~chimeric~~ antibody or antigen-binding fragment thereof comprises ~~two light chains and two heavy chains, each of said chains comprising at least part of a human constant region and at least part of a human variable region, said variable region capable of binding an epitope of human TNF $\alpha$ .~~

Claims 18-29. (Canceled).

30. (New) The antibody or antigen-binding fragment of Claim 1, which comprises at least one human light chain and at least one human heavy chain.

31. (New) The antibody or antigen-binding fragment of Claim 30, wherein the light chain comprises all antigen-binding regions of the light chain of A2 (ATCC Accession No. PTA-7045).

32. (New) The antibody or antigen-binding fragment of Claim 30, wherein the heavy chain comprises all antigen-binding regions of the heavy chain of A2 (ATCC Accession No. PTA-7045).

33. (New) The antibody or antigen-binding fragment of Claim 30, wherein the light chain comprises all antigen-binding regions of the light chain of A2 (ATCC Accession No. PTA-7045) and the heavy chain comprises all antigen-binding regions of the heavy chain of A2 (ATCC Accession No. PTA-7045).

34. (New) An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC Accession No. PTA-7045), and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant ( $K_a$ ).
35. (New) A composition comprising the antibody or antigen-binding fragment of Claim 1, and a pharmaceutically acceptable carrier.
36. (New) The antibody or antigen-binding fragment of Claim 1, which is of immunoglobulin class IgG1, IgG2, IgG3, IgG4 or IgM.
37. (New) The antigen-binding fragment of Claim 1, wherein said fragment is selected from the group consisting of Fab, Fab', F(ab')<sub>2</sub> and Fv.
38. (New) The antibody or antigen-binding fragment of Claim 15, which comprises at least one human light chain and at least one human heavy chain.
39. (New) The antibody or antigen-binding fragment of Claim 38, wherein the light chain comprises all antigen-binding regions of the light chain of A2 (ATCC Accession No. PTA-7045).
40. (New) The antibody or antigen-binding fragment of Claim 38, wherein the heavy chain comprises all antigen-binding regions of the heavy chain of A2 (ATCC Accession No. PTA-7045).
41. (New) The antibody or antigen-binding fragment of Claim 38, wherein the light chain comprises all antigen-binding regions of the light chain of A2 (ATCC Accession No. PTA-7045) and the heavy chain comprises all antigen-binding regions of the heavy chain of A2 (ATCC Accession No. PTA-7045).
42. (New) An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human IgG1 constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC

Accession No. PTA-7045), and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant ( $K_a$ ).

43. (New) A composition comprising the antibody or antigen-binding fragment of Claim 15 and a pharmaceutically acceptable carrier.
44. (New) An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human IgG4 constant region, wherein said antibody or antigen-binding fragment (i) competitively inhibits binding of A2 (ATCC Accession No. PTA-7045) to human TNF $\alpha$ , and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $10^8$  liter/mole, measured as an association constant ( $K_a$ ).
45. (New) An isolated recombinant anti-TNF- $\alpha$  antibody or antigen-binding fragment thereof, said antibody comprising a human IgG4 constant region, wherein said antibody or antigen-binding fragment (i) comprises the antigen-binding regions of A2 (ATCC Accession No. PTA-7045), and (ii) binds to human TNF- $\alpha$  with an affinity of at least  $1 \times 10^8$  liter/mole, measured as an association constant ( $K_a$ ).